Podcast

On Kidney Cancer Advocacy: ‘There’s Only One Way to Go, and That’s Forward’

If an oncologist was apprehensive about Steven Edwards getting a second opinion, that might not be the right doctor for him, the kidney cancer survivor said.

After being diagnosed with kidney cancer — which was a possible result of exposure to the 9/11 terrorist attacks in New York City – Steven Edwards realized that he had to be his own advocate. Pivotal to his advocacy was asking questions and getting as many professional opinions as possible.

“I probably would consider whether it was the right doctor for me in the first place if a doctor was upset about getting a second opinion, because it’s all about gathering education and becoming educated yourself,” Edwards said in an interview with CURE®.

Edwards went through multiple different treatments, including the participation on a clinical trial, and continues to push for better outcomes for himself and other survivors through being an advocate for the Kidney Cancer Association and KidneyCAN.

Through cancer setbacks like a diagnosis of metastatic disease in 2017, classifying Edwards’ disease as stage 4, he continues to seek information in this rapidly changing field. After all, “There’s only way to go, and that’s forward,” Edwards said.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Image of a man wearing a black suit and tie.
Image of a man with rectangular glasses and a goatee.
Image of a woman with a brown hair tied into a bun.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Related Content